Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.

Zhen Zeng, Jundong Li, Wei Wei et al.|Journal of Clinical Oncology|2023

Cited by 0